Complementary and alternative medicine: Risks and special considerations in pretransplant and posttransplant patients

Nutrition in Clinical Practice

Volumn 29, Issue 3, 2014, Pages 322-331

  Corey, Rebecca L ^a   Rakela, Jorge ^a  

^a MAYO CLINIC   (United States)

Author keywords

complementary therapies; herb drug interactions; herbal medicine; organ transplantation; transplantation; transplants

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ARISTOLOCHIC ACID; CASCARA SAGRADA; CYCLOSPORIN; DAISAIKOTO; DECONGESTIVE AGENT; DIURETIC AGENT; EPHEDRINE; EVEROLIMUS; GREEN TEA EXTRACT; HERBACEOUS AGENT; IMMUNOSUPPRESSIVE AGENT; KAVA; MAGNESIUM; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEEM OIL; PRESCRIPTION DRUG; PYRROLIZIDINE ALKALOID; RAPAMYCIN; TACROLIMUS; VALERIAN; XIAO CHAI HU TANG; PLANT MEDICINAL PRODUCT;

ACTAEA RACEMOSA; ALLOPATHY; ALTERNATIVE MEDICINE; ARTICLE; ATHLETIC PERFORMANCE; BREATHING EXERCISE; CALLILEPIS; CAMELLIA SINENSIS; CARDIOTOXICITY; CHELIDONIUM; CHIROPRACTIC; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CHRONIC PATIENT; DIET SUPPLEMENTATION; EPHEDRA SINICA; GERMANDER; GLYCYRRHIZA GLABRA; GOOD MANUFACTURING PRACTICE; GRAFT RECIPIENT; HEALTH CARE PERSONNEL; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; LIVER TOXICITY; MINERAL INTAKE; MORINDA CITRIFOLIA; NATIONAL HEALTH ORGANIZATION; NEPHROTOXICITY; NONALCOHOLIC FATTY LIVER; ORGAN TRANSPLANTATION; PIPER METHYSTICUM; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PREVALENCE; PREVENTION; SABAL; SOUR ORANGE; TEUCRIUM CHAMAEDRYS; UNITED STATES; VISCUM ALBUM; ADVERSE EFFECTS; LEGISLATION AND JURISPRUDENCE; PHYTOTHERAPY; PROCEDURES; STANDARDS;

COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; HUMANS; PHYTOCHEMICALS; PHYTOTHERAPY; TRANSPLANT RECIPIENTS; UNITED STATES;

EID: 84900397186     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533614528007     Document Type: Article

References (85)

1. Washington, DC: Government Printing Office ; 1994:
2. Nahin RL, Barnes PM, Stussman BJ, Bloom B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States. Natl Health Stat Rep. 2007 ; 2009: 1-14
3. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States. Natl Health Stat Rep. 2007 ; 2008: 1-23
4. Barnes PM, Powell-Griner E, McFann K, Nahin RL Hyattsville, Maryland: National Center for Health Statistics ; 2004:
5. Gahche J, Bailey R, Burt V, et al. Dietary supplement use among U.S. adults has increased since NHANES III (1988-1994). NCHS Data Brief. 2011 ;: 1-8
6. Nutrition Business Journal Supplement Business Report2012. http://newhope360.com/site-files/newhope360.com/files/uploads/2013/04/ TOC-SUMM120928.supp%20report%20FINAL%20standard.pdf. Accessed December 12, 2013.
7. Nahin RL, Dahlhamer JM, Taylor BL, et al. Health behaviors and risk factors in those who use complementary and alternative medicine. BMC Public Health. 2007 ; 7: 217
8. Bailey RL, Gahche JJ, Miller PE, Thomas PR, Dwyer JT.. Why US adults use dietary supplements. JAMA Intern Med. 2013 ; 173: 355-361
9. AARP and National Center for Complementary and Alternative Medicine Survey Report. Complementary and alternative medicine: what people aged 50 and older discuss with their health care providers. http://nccam.nih.gov/sites/ nccam.nih.gov/files/news/camstats/2010/NCCAM-aarp-survey.pdf?nav=gsa. Accessed December 19, 2013.
10. Marinac JS, Buchinger CL, Godfrey LA, Wooten JM, Sun C, Willsie SK. Herbal products and dietary supplements: a survey of use, attitudes, and knowledge among older adults. J Am Osteopath Assoc. 2007 ; 107: 13 1-20 3
11. van den Brink-Muinen A, Rijken PM. Does trust in health care influence the use of complementary and alternative medicine by chronically ill people?. BMC Public Health. 2006 ; 6: 188
12. Gardiner P, Graham RE, Legedza AT, Eisenberg DM, Phillips RS. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med. 2006 ; 166: 1968-1974
13. Busse JW, Heaton G, Wu P, Wilson KR, Mills EJ. Disclosure of natural product use to primary care physicians: a cross-sectional survey of naturopathic clinic attendees. Mayo Clinic Proc. 2005 ; 80: 616-623
14. Foroncewicz B, Mucha K, Gryszkiewicz J, et al. Dietary supplements and herbal preparations in renal and liver transplant recipients. Transplant Proc. 2011 ; 43: 2935-2937
15. Ferrucci LM, Bell BP, Dhotre KB, et al. Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol. 2010 ; 44: e40 - e45
16. FDA 101: dietary supplements. Consumer health information. http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/ucm050824.pdf. Accessed December 20, 2013.
17. Final Rule. Fed Regist. 2004 ; 69: 6787-854
18. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000 ; 343: 1833-1838
19. Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med. 2003 ; 138: 468-471
20. Kalman DS, Antonio J, Kreider RB. The relative safety of ephedra compared with other herbal products. Ann Intern Med. 2003 ; 138: 1006-1007
21. Final Rule Promotes safe use of dietary supplements. FDA consumer health information. June22, 2007. http://www.fda.gov/downloads/ForConsumers/ ConsumerUpdates/UCM143584.pdf. Accessed December 12, 2013.
22. Morris CA, Avorn J. Internet marketing of herbal products. JAMA. 2003 ; 290: 1505-1509
23. Blendon RJ, DesRoches CM, Benson JM, Brodie M, Altman DE. Americans' views on the use and regulation of dietary supplements. Arch Intern Med. 2001 ; 161: 805-810
24. Buettner C, Mukamal KJ, Gardiner P, Davis RB, Phillips RS, Mittleman MA. Herbal supplement use and blood lead levels of United States adults. J Gen Intern Med. 2009 ; 24: 1175-1182
25. Tainted products marketed as dietary supplements. FDA consumer health information, December2010. http://www.fda.gov/downloads/ForConsumers/ ConsumerUpdates/UCM236998.pdf./Accessed December 13, 2013.
26. Mullin GE. The use of complementary and alternative medicine for liver disease: part II. Nutr Clin Pract. 2013 ; 28: 277-279
27. Gloro R, Hourmand-Ollivier I, Mosquet B, et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol. 2005 ; 17: 1135-1137
28. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000 ; 342: 1686-1692
29. Stimulant potentially dangerous to health, FDA Warns. FDA consumer health information. April, 2013. http://www.fda.gov/downloads/ForConsumers/ ConsumerUpdates/UCM347700.pdf. Accessed December 12, 2013.
30. Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, Wang JD. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. Am J Kidney Dis. 2010 ; 55: 507-518
31. Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis. 2000 ; 35: 313-318
32. Teschke R, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol. 2013 ; 19: 2864-2882
33. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008 ; 371: 2173-2182
34. Jimenez-Saenz M, Martinez-Sanchez Mdel C. Acute hepatitis associated with the use of green tea infusions. J Hepatol. 2006 ; 44: 616-617
35. Molinari M, Watt KD, Kruszyna T, et al. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl. 2006 ; 12: 1892-1895
36. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol. 2005 ; 43: 901-910
37. Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg. 2003 ; 138: 852-858
38. OxyElite Pro supplements recalled. Consumer health information. http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM375497.pdf. Accessed December 12, 2013.
39. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation. 2001 ; 71: 239-241
40. Laird J. Interactions between supplements and drugs: deciphering the evidence. JAAPA. 2011 ; 24: 44 48-46 49
41. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001 ; 61: 2163-2175
42. Kanji S, Seely D, Yazdi F, et al. Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review. Syst Rev. 2012 ; 1: 26
43. CDC Health Alert Network. Acute hepatitis and liver failure following the use of a dietary supplement intended for weight loss or muscle building. http://www.bt.cdc.gov/HAN/han00356.asp. Accessed December 12, 2013.
44. MMWR Morb Mortal Wkly Rep. 2013 ; 62: 817-819
45. DMAA in dietary supplements. FDA Q & A on dietary supplements, July16, 2013. http://www.fda.gov/Food/DietarySupplements/QADietarySupplements/ ucm346576.htm. Accessed February 18, 2014.
46. Violi F, Pignatelli P, Basili S. Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation. 2010 ; 121: 1033-1044
47. Stanger MJ, Thompson LA, Young AJ, Lieberman HR. Anticoagulant activity of select dietary supplements. Nutr Rev. 2012 ; 70: 107-117
48. Kaye AD, Clarke RC, Sabar R, et al. Herbal medicines: current trends in anesthesiology practice - a hospital survey. J Clin Anesth. 2000 ; 12: 468-471
49. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001 ; 286: 208-216
50. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009 ; 69: 1777-1798
51. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002 ; 54: 349-356
52. Nowack R. Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's wort - and beyond!. Nephrology. 2008 ; 13: 337-347
53. Alscher DM, Klotz U. John's wort with cyclosporine. Transplant Int. 2003 ; 16: 543-544
54. Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. Am J Kidney Dis. 2001 ; 38: 1105-1107
55. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J. Drug interaction of St John's wort with cyclosporin. Lancet. 2000 1912 ; 355:
56. Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Transplantation. 2000 ; 69: 2229-2230
57. Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant. 2003 ; 18: 819-822
58. Ernst E. St John's wort supplements endanger the success of organ transplantation. Arch Surg. 2002 ; 137: 316-319
59. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003 ; 42: 59-98
60. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003 ; 290: 1500-1504
61. Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther. 2004 ; 76: 330-340
62. Warning on Hydroxycut products. Consumer health information. http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM152222.pdf. Accessed February 18, 2014.
63. Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med. 2006 ; 144: 68-71
64. Stickel F, Kessebohm K, Weimann R, Seitz HK. Review of liver injury associated with dietary supplements. Liver Int. 2011 ; 31: 595-605
65. Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal weight-loss supplement Hydroxycut. Ann Intern Med. 2005 ; 142: 477-478
66. Bjornsson E, Olsson R. Serious adverse liver reactions associated with herbal weight-loss supplements. J Hepatol. 2007 ; 47: 295-298
67. Elinav E, Pinsker G, Safadi R, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol. 2007 ; 47: 514-520
68. Mattei A, Rucay P, Samuel D, Feray C, Reynes M, Bismuth H. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. J Hepatol. 1995 ; 22: 597
69. Graham-Brown R. Toxicity of Chinese herbal remedies. Lancet. 1992 ; 340: 673-674
70. Starakis I, Siagris D, Leonidou L, Mazokopakis E, Tsamandas A, Karatza C. Hepatitis caused by the herbal remedy. Teucrium polium L. Eur J Gastroenterol Hepatol. 2006 ; 18: 681-683
71. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013 ; 37: 3-17
72. Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med. 2002 ; 136: 590-595
73. Laliberte L, Villeneuve JP. Hepatitis after the use of germander, an herbal remedy. CMAJ. 1996 ; 154: 1689-1692
74. Skoulidis F, Alexander GJ, Davies SE. Ma Huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol. 2005 ; 17: 581-584
75. Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of Ma Huang. Am J Gastroenterol. 2001 ; 96: 1654-1655
76. Larrey D, Vial T, Pauwels A, et al. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med. 1992 ; 117: 129-132
77. Woolf GM, Petrovic LM, Rojter SE, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med. 1994 ; 121: 729-735
78. Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf. J Clin Gastroenterol. 1990 ; 12: 203-206
79. Gordon DW, Rosenthal G, Hart J, Sirota R, Baker AL. Chaparral ingestion: the broadening spectrum of liver injury caused by herbal medications. JAMA. 1995 ; 273: 489-490
80. Horowitz RS, Feldhaus K, Dart RC, Stermitz FR, Beck JJ. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med. 1996 ; 156: 899-903
81. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med. 1997 ; 157: 913-919
82. Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl. 2006 ; 12: 989-992
83. Levitsky J, Alli TA, Wisecarver J, Sorrell MF. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci. 2005 ; 50: 538-589
84. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann KH. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol. 2011 ; 10: 249-259
85. Seeff LB. Herbal hepatotoxicity. Clin Liver Dis. 2007 ; 11: 577-596